ALLOS THERAPEUTICS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | |
|---|---|---|---|
| Revenue | $76.0M | $35.2M | $3.6M |
| Operating income | −$30.6M | −$79.0M | −$74.0M |
| Net income | −$30.5M | −$77.4M | −$73.6M |
| Total assets | $122.1M | $120.8M | — |
| Total liabilities | — | — | — |
| Equity | $79.3M | $98.2M | $159.5M |
| EPS (diluted) | — | — | — |
| Shares out. | 106.3M | 105.5M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −40.3%
- Net margin
- −40.1%
- Return on equity
- −38.5%
- Return on assets
- −25.0%
- Return on capital (ROCE)
- −30.3%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.75
- Revenue growth (YoY)
- 115.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Accruals / assets
- −24.4%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 15, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Spectrum Pharmaceuticals Inc10% owner | Sep 5, 2012 | Buy | 130.9M | $1.82 |
| Warburg Pincus Private Equity Viii, L.P.Director | Sep 5, 2012 | U | 26.1M | $1.82 |
| Turner Joseph LDirector | Sep 4, 2012 | U | 55,000 | $1.82 |
| Stout David MDirector | Sep 4, 2012 | U | 35,000 | $1.82 |
| Leff Jonathan SDirector | Sep 4, 2012 | U | 55,000 | $1.82 |
| Latts JeffreyDirector | Sep 4, 2012 | U | 55,000 | $1.82 |
| Hoffman Stephen JDirector | Sep 4, 2012 | U | 92,000 | $1.82 |
| Schick Michael EOfficer — VP, Sales and Marketing | Sep 4, 2012 | U | 285,113 | $1.82 |
| Morris Charles QOfficer — Chief Medical Officer | Sep 4, 2012 | U | 655,031 | $1.82 |
| Goldsmith Bruce AOfficer — SVP, Corporate Development | Sep 4, 2012 | U | 346,933 | $1.82 |
| Graboyes Marc HOfficer — SVP, General Counsel | Sep 4, 2012 | U | 542,028 | $1.82 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 5, 2012
- Other material eventJun 27, 2012
- Other material eventApr 20, 2012
- Entered a material agreement · Director / officer changeApr 6, 2012
- Prior financials not reliable (restatement)Mar 19, 2012
- Results of operationsMar 6, 2012
- Director / officer changeMar 5, 2012
- Director / officer changeFeb 24, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERSep 26, 2017
- CT ORDERSep 20, 2016
- SC 13G/ASCHEDULE 13G AMENDMENTOct 9, 2012
- 15-12GFORM 15Sep 17, 2012
- 4FORM 4Sep 6, 2012
- 3FORM 3Sep 6, 2012
- 3FORM 3Sep 6, 2012
- 3FORM 3Sep 6, 2012
- SC 13D/AAMENDMENT NO. 5Sep 6, 2012
- 4FORM 4Sep 6, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Sep 6, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Sep 6, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Sep 6, 2012
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Sep 6, 2012
- 8-KFORM 8-KSep 5, 2012